<DOC>
	<DOCNO>NCT02135432</DOCNO>
	<brief_summary>The study randomize , double-blind , placebo-controlled , multiple-dose , pilot study orally-administered ivacaftor subject chronic obstructive pulmonary disease . Subjects administer study drug ivacaftor 150 mg ( placebo ) twice daily ( BID ) .</brief_summary>
	<brief_title>TOPIC Trial COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Male Female age 4065 A clinical diagnosis COPD define GOLD At Least 10 pack year smoke history Exhibit symptom chronic bronchitis define MRC FEV1 % predict ≥ 35 % ≤70 % Post Bronchodilator Clinically stable last 4 week evidence COPD exacerbation Weight 40 kg120 kg Willingness use least one form acceptable birth control include abstinence , condom spermicide , hormonal contraceptive Willing monitor blood glucose know history diabetes mellitus require insulin medical therapy Current Diagnosis Asthma Daytime use Oxygen Therapy Documented history drug abuse within last year Subjects pulmonary exacerbation change therapy pulmonary disease within 28 day receive first dose study drug . Cirrhosis elevate liver transaminase &gt; 3X ULN GFR &lt; 50 estimate CockcroftGault Any illness abnormal lab finding , opinion investigator subject 's general practitioner , might confound result study pose additional risk administer study drug subject . Pregnant Breastfeeding Subjects take inhibitor inducer CYP3A4 , include certain herbal medication grapefruit/grapefruit juice . Uncontrolled Diabetes Excluded medication food include drug food provide appendix document . Clinically significant arrhythmias conduction abnormality opinion investigator affect patient safety add exclusion criterion criterion withdrawal . Patients stable hospitalize past 3 month clinically significant cardiac condition . Subjects history cancer ( current past , unless remote ( &gt; 5years ) ) except localize nonmelanomatous skin cancer History Stroke/CVA History myocardial infarction/acute coronary syndrome Cardiac Failure NYHC grade IIIIV Diabetes Type I Uncontrolled Hypertension Primary secondary pulmonary hypertension</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Chronic Obstructive pulmonary disease , Ivacaftor</keyword>
</DOC>